1. Home
  2. ABUS vs EVC Comparison

ABUS vs EVC Comparison

Compare ABUS & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.35

Market Cap

836.0M

Sector

Health Care

ML Signal

HOLD

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

HOLD

Current Price

$6.37

Market Cap

683.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
EVC
Founded
2005
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
836.0M
683.9M
IPO Year
2008
2000

Fundamental Metrics

Financial Performance
Metric
ABUS
EVC
Price
$4.35
$6.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 6.3M
1.1M
Earning Date
11-12-2026
11-03-2026
Dividend Yield
N/A
★ 3.17%
EPS Growth
★ 55.26
47.59
EPS
★ 0.84
0.32
Revenue
$14,083,000.00
★ $536,034,000.00
Revenue This Year
$1,208.75
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ $4.98
$19.09
Revenue Growth
★ 128.21
N/A
52 Week Low
$3.50
$1.95
52 Week High
$5.45
$13.74

Technical Indicators

Market Signals
Indicator
ABUS
EVC
Relative Strength Index (RSI) 35.56 25.22
Support Level $4.17 $2.90
Resistance Level $4.57 $10.09
Average True Range (ATR) 0.18 0.34
MACD -0.02 -0.03
Stochastic Oscillator 15.43 3.40

Price Performance

Historical Comparison
ABUS
EVC

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: